GNL Gut and Liver
  1. Jieun Lee, Jeong-Ju Yoo. The current state of graphical abstracts and how to create good graphical abstracts. Sci Ed 2023;10:19
    https://doi.org/10.6087/kcse.293
  2. Younghee Choe. Antibiotic Resistance and Helicobacter pylori Eradication Therapy. Korean J Helicobacter Up Gastrointest Res 2023;23:218
    https://doi.org/10.7704/kjhugr.2023.0044
  3. E. A. Ortenberg, M. V. Lyapina, E. F. Dorodnyeva. Competitive proton pump inhibitors - status and Prospects of use. jour 2023:86
    https://doi.org/10.31146/1682-8658-ecg-212-4-86-92
  4. Hye Kyung Jeon, Gwang Ha Kim, Yong-Il Cheon, Sung-Chan Shin, Byung Joo Lee. Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study. JCM 2023;12:6116
    https://doi.org/10.3390/jcm12196116
  5. Jin Hee Noh, Kee Don Choi. Vonoprazan-based Dual and Triple Therapy for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2023;23:228
    https://doi.org/10.7704/kjhugr.2023.0022
  6. Seong Hyun Cho, Moon Sik Park, Seon-Young Park, Dong Hyun Kim, Hye-Su You, Hyun-Soo Kim. Effectiveness of 7-day triple therapy with half-dose clarithromycin for the eradication of Helicobacter pylori without the A2143G and A2142G point mutations of the 23S rRNA gene in a high clarithromycin resistance area. Front. Med. 2023;10
    https://doi.org/10.3389/fmed.2023.1150396
  7. Byeong Yun Ahn, Soo-Jeong Cho. Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2023;23:174
    https://doi.org/10.7704/kjhugr.2023.0041
  8. Caio Constantini Rosa, Jessé Rodrigues de Moraes. Tratamento Das Infecções Por Helicobacter Pylori: Revisão De Ensaios Clínicos. jmrr 2022;1:e021
    https://doi.org/10.37497/JMRReview.v1i1.21
  9. Yoon Jin Choi. Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers. Korean J Gastroenterol 2022;80:247
    https://doi.org/10.4166/kjg.2022.143
  10. Fumiaki Ishibashi, Sho Suzuki, Mizuki Nagai, Kentaro Mochida, Tetsuo Morishita. Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments. Gut and Liver 2023;17:684
    https://doi.org/10.5009/gnl220429
  11. Yuichiro Noiri, Ryoko Nagata. Current status of gastric and oral infection/diseases caused by Helicobacter pylori. Oral Science International 2023;20:182
    https://doi.org/10.1002/osi2.1172
  12. Sung Eun Kim. Approach to Patients with Consecutive Helicobacter pylori Eradication Failure. Korean J Helicobacter Up Gastrointest Res 2023;23:15
    https://doi.org/10.7704/kjhugr.2023.0017
  13. Joon Sung Kim, Weonjin Ko, Jun‐Won Chung, Tae Ho Kim. Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study. Helicobacter 2023;28
    https://doi.org/10.1111/hel.12977
  14. Abdullah Shah, Omer Usman, Tafseer Zahra, Sandipkumar S Chaudhari, Gopi Sairam Reddy Mulaka, Rumaisa Masood, Saima Batool, Faraz Saleem. Efficacy and Safety of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors as Helicobacter pylori Eradication Therapy: A Meta-Analysis of Randomized Clinical Trials. 2023
    https://doi.org/10.7759/cureus.48465
  15. György Miklós Buzás, Péter Birinyi. Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review. Antibiotics 2023;12:946
    https://doi.org/10.3390/antibiotics12060946
  16. Yong Hwan Kwon, Seong Woo Jeon, Su Youn Nam, Dong Wook Lee, Ji Hey Park, Hui Jin Bae. Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication. Korean J Intern Med 2023;38:493
    https://doi.org/10.3904/kjim.2022.345
  17. Jin Lee. Role of Tegoprazan in Helicobacter pylori Eradication Therapy. Gut and Liver 2022;16:493
    https://doi.org/10.5009/gnl220272
  18. Zhuodu Wei, Hyeon-Cheol Jeong, Min-Gul Kim, Kwang-Hee Shin. Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model. Pharmaceuticals 2023;16:360
    https://doi.org/10.3390/ph16030360
  19. Jong Kyu Park. Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers. Korean J Helicobacter Up Gastrointest Res 2023;23:180
    https://doi.org/10.7704/kjhugr.2023.0034
  20. Yoon Suk Jung, Sunyong Kim, Hyun-Young Kim, Seung Jae Noh, Jung Ho Park, Chong Il Sohn, Chan Hyuk Park. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study. Gut and Liver 2023;17:711
    https://doi.org/10.5009/gnl220218
  21. Hyun Ho Choi. Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?. Gut and Liver 2023;17:668
    https://doi.org/10.5009/gnl230338
  22. Chan Hyuk Park, Myung Jin Song, Byung Wook Jung, Jung Ho Park, Yoon Suk Jung. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. JPM 2022;12:1918
    https://doi.org/10.3390/jpm12111918
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd